<DOC>
	<DOCNO>NCT01984008</DOCNO>
	<brief_summary>The primary objective study demonstrate investigation medication ( Bowklean ) less effective active comparator ( Klean-Prep Dulcolax ) , regard overall quality bowel preparation subject undergoing colonoscopy . An additional objective study collect subject 's response acceptability tolerability bowel preparation safety information . After bowel preparation , independent evaluator blind subject 's treatment evaluate overall colon cleansing base Aronchick Ottawa scale . A total 600 eligible subject schedule colonoscopy randomly assign equal allocation 1 2 treatment group : `` Bowklean '' `` Klean-Prep '' Dulcolax . Each subject 's participation expect maximally 4 week study duration ( 3-week screening period follow one week post colonoscopy ) .</brief_summary>
	<brief_title>A Prospective , Randomized Controlled Clinical Study Efficacy Safety Bowklean Klean-Prep With Dulcolax Bowel Preparation Prior Colonoscopy</brief_title>
	<detailed_description />
	<mesh_term>Magnesium Oxide</mesh_term>
	<mesh_term>Picosulfate sodium</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Subject 20 80 year , inclusive . Men nonpregnant woman schedule elective colonoscopy . Subjects willing , able complete entire procedure comply study instruction . Written inform consent obtain prior study . Acute surgical abdominal condition ( e.g . acute obstruction perforation , etc . ) Active ( acute/exacerbation of/severe/uncontrolled ) Inflammatory Bowel Disease ( IBD ) Colon disease ( history colonic cancer , toxic megacolon , toxic colitis , idiopathic pseudo obstruction , hypomotility syndrome ) Gastrointestinal disorder ( active ulcer , outlet obstruction , gastric retention , gastroparesis , ileus ) Any prior colorectal surgery past 3 month , exclude appendectomy , hemorrhoid surgery prior endoscopic procedure History upper gastrointestinal surgery ( gastric resection , gastric banding , gastric bypass ) Severe chronic constipation Ascites Renal insufficiency ( ( serum creatinine &gt; 1.5 time upper limit normal ( ULN ) ) creatinine clearance &lt; 30 mL/min ) Uncontrolled angina and/or Myocardial Infarction ( MI ) within last 3 month randomization , Congestive Heart Failure ( CHF ) , uncontrolled hypertension Participation investigational study within 60 day prior receive study medication Any clinically significant laboratory value screening , include preexist electrolyte abnormality , base clinical history Investigator feel may affect study evaluation Hypersensitivity ingredient study medication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>